Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 5583 Treatment of Headaches and Chronic Migraines

I am writing to you today to request information regarding the treatment of Headaches and Chronic Migraines.
1. Could you please provide me with the following numbers of patients treated in the last 6 months, with the following drugs for Chronic Migraine. If none, please state None.
a) Botox
b) Dysport
c) Xeomin

None.

2. Does your trust treat migraine with any of the following treatments? If so, how many patients in the last 6 months?
a) Topiramate / anticonvulsants
b) Beta-blockers / propranolol
c) Calcium channel blockers
d) Anti-serotonergics
e) Tricyclic anti-depressants / amitriptyline
f) Candesartan / angiotensin II inhibitors

We do treat patients for migraines with the above treatments, however we do not hold the number of patients.

3. Does your trust run any botulinum A [botox] clinics (regardless of any indication or department)?

Yes.

4. Does your organisation run any Clinics where patients have treatment for Headaches and Chronic Migraines? 

Yes

IF YES PLEASE PROVIDE THE FOLLOWING.

a) What is the name of these clinics?

General Neurology Clinics

b) Which department runs the clinic?

Neurology

c) At which locations are these clinics run? Please provide address and postcode where possible.

3 Sites: Solihull Hospital, Good Hope Hospital, and Birmingham Heartlands Hospital

d) How frequently are these clinics run?

Daily

e) What is the average number of Chronic Migraine (CM) patients seen per clinic (based on last 6 months data)?

Not Applicable

f) Do any of these clinics use Botulinum A [botox] to manage the pain of headaches and chronic migraines?

No

5. Please see attached PDF FOI 5583

 

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.